More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

Jacqueline Corrigan-Curay, who serves as acting head of the powerful CDER office, will leave after nearly a decade at the ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...